Description

Finerenone CAS NO 1050477-31-0 is a highly selective, non-steroidal mineralocorticoid receptor antagonist (MRA) of significant therapeutic interest. It is specifically designed to address cardiorenal risk in patients with chronic kidney disease associated with type 2 diabetes, offering a targeted mechanism of action. This active pharmaceutical ingredient (API) is essential for pharmaceutical manufacturers and research institutions developing next-generation treatments for diabetic kidney disease and heart failure.

Application

• Pharmaceutical API: Primary use as the active ingredient in finished dosage forms for the treatment of chronic kidney disease associated with type 2 diabetes.
• Cardiorenal Protection: Key component in medications aimed at reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure.
• Clinical Research: Critical reference standard and raw material for preclinical and clinical studies exploring mineralocorticoid receptor antagonism.
• Formulation Development: Used in R&D for developing various solid oral dosage forms, such as tablets.
• Comparative Studies: Serves as a benchmark in pharmacological research against other steroidal and non-steroidal MRAs.

Basic Information

Product Name	Finerenone
CAS No.	1050477-31-0
Molecular Formula	C21H22FN3O4
Molecular Weight	399.42 g/mol
Synonyms	BAY 94-8862; (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide; 1,4-Dihydro-2-methyl-4-(4-cyano-2-methoxyphenyl)-6-methyl-5-(ethylcarbamoyl)-3-pyridinecarboxylic acid methyl ester; Kerendia (Brand Name); Finerenonum; Finerenon
EINECS	Contact for details

Quality Control

Our Finerenone is manufactured under strict quality management systems, targeting high purity suitable for pharmaceutical development. Quality is assured through comprehensive analytical testing, including HPLC for assay and impurity profiling, residual solvent analysis, and identification tests. A Certificate of Analysis (COA) detailing batch-specific results is provided with every shipment, ensuring traceability and compliance with cGMP principles and ICH guidelines.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider desiccants or inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Retention time corresponds to reference
Assay (HPLC)	≥98.5%
Related Substances (HPLC)	Total impurities ≤1.5% Any single unknown impurity ≤0.10%
Residual Solvents (GC)	Complies with ICH Q3C
Loss on Drying	≤0.5%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.